Laurus Labs Limited
LAURUSLABS.NS
INR1 004.10 -2.14%
Exchange: NSE | Sector: Healthcare | Industry: Drug Manufacturers Specialty Generic
Q2 2024
Published: Sep 30, 2024

Earnings Highlights

  • Revenue of $12.24B down 0.1% year-over-year
  • EPS of $0.37 decreased by 46.4% from previous year
  • Gross margin of 55.2%
  • Net income of 198.40M
  • ""Our focus remains on the development of niche products and sustaining growth in our core APIs, particularly in oncology and antiretroviral segments."" - Management
LAURUSLABS.NS
Laurus Labs Limited

Executive Summary

Laurus Labs Limited reported a revenue of ₹12,237 million for Q2 2024, reflecting a slight decrease of 0.06% year-over-year (YoY) but a notable improvement of 2.41% quarter-over-quarter (QoQ). The company’s gross profit surged by 4.98% YoY and increased strongly by 78.67% QoQ, reaching ₹6,754 million, yielding a robust gross margin of 55.2%. However, net income witnessed a significant decline of 46.31% YoY, settling at ₹198 million due to elevated operational costs and a decrease in operational income by 26.44% YoY. Management is focused on operational efficiencies and expanding specialty therapeutics to improve profit margins going forward, addressing investor concerns about profitability amidst rising costs.

Key Performance Indicators

Revenue
Decreasing
12.24B
QoQ: 2.41% | YoY: -0.06%
Gross Profit
Increasing
6.75B
55.19% margin
QoQ: 78.67% | YoY: 4.98%
Operating Income
Decreasing
708.20M
QoQ: 8.72% | YoY: -26.44%
Net Income
Decreasing
198.40M
QoQ: 58.59% | YoY: -46.31%
EPS
Decreasing
0.37
QoQ: 60.87% | YoY: -46.38%

Revenue Trend

Margin Analysis

Historical Earnings Comparison

PeriodRevenue ($M)EPS ($)YoY GrowthReport
Q1 2026 15,695.70 3.02 +9.0% View
Q3 2024 14,150.50 1.71 +18.4% View
Q2 2024 12,237.00 0.37 -0.1% View
Q1 2024 11,949.10 0.23 +1.1% View
Q4 2023 13,809.00 1.91 +4.3% View